盐酸多柔比星脂质体注射液联合注射用紫杉醇(白蛋白结合型)致严重皮肤损害1例分析

目的 提醒临床医生在联合使用多柔比星脂质体和紫杉醇(白蛋白结合型)时应密切关注用药安全.方法 分析了1例43岁女性患者联合使用多柔比星脂质体和紫杉醇(白蛋白结合型)后出现3级手足综合征和2级皮肤擦烂样皮炎的病例,文献回顾上述2种药物所致皮肤毒性的临床表现、发病机制和防治措施.结果 该患者的手足综合征很可能由多柔比星脂质...

One Case of Severe Skin Damage Induced by Combination of Doxorubicin Hydrochloride Liposome Injection and Paclitaxel for Injection(albumin-binding)

Objective To remind clinicians to pay close attention to medication safety when doxorubicin liposomes and paclitaxel(albumin-bound type)are used in combination.Methods One case of a 43-yearold female patient with grade 3 hand-foot syndrome and grade 2 intertrigo-like eruption after combined use of doxorubicin liposome and paclitaxel(albumin-bound type)was analyzed.Literature about the clinical manifestations,pathogenesis and prevention of skin toxicity caused by the above two drugs was reviewed.Results The patient's hand-foot syndrome was probably caused by doxorubicin liposomes,and the intertrigolike eruption by the combined use of doxorubicin liposomes and paclitaxel(albumin-bound).After such symptomatic interventions as dose reduction,delayed chemotherapy and traditional Chinese medicine,the patient's skin symptoms were gradually relieved.Conclusion The combined use of doxorubicin liposomes and paclitaxel(albumin-bound type)may cause serious skin toxicity and impact the quality of life of patients,which deserves the attention of clinicians.Patients should be better informed of the related risk and take precautions.